Amendments to the Claims:

The following is a complete list of claims indicating the changes incorporated by the present amendment and replacing all prior versions of the claims. Any claims canceled herein and all deletions made in claims that are not canceled herein are done so without prejudice to being re-instituted at a later date in this or a related application.

Listing of Claims:

1-69. (Canceled)

70. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of ~~**any one of Claims 1-18 and**~~ **claim** 119.

71-118. (Canceled)

119. (Currently Amended) A compound having a formula (I):



(I)

and their pharmaceutically acceptable salts, wherein

R^1 is a member selected from the group consisting of **phenyl** ~~**aryl**~~ and heteroaryl;

P^1 is a primary pharmacophore selected from the group consisting of —NHC(O)NH—, -OC(O)NH—, —NHC(O)O—, —CH_2C(O)NH—, —C(O)NH— and —NHC(O)—;

P^2 is a secondary pharmacophore selected from the group consisting of —C(O)—, —CH(OH)—, —$O(CH_2CH_2O)_q$—, —C(O)O—, —OC(O)—, —NHC(O)NH—, —OC(O)NH—, -NHC(O)O—, —C(O)NH— and —NHC(O)—;

P^3 is a tertiary pharmacophore selected from the group consisting of C_2-C_6 alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, —C(O)NHR[1], —C(O)NHS$(O)_2R^1$, —NHS$(O)_2R^2$,

-C(O)OR^2 and carboxylic acid analogs, wherein R^2 is a member selected from the group consisting of hydrogen, unsubstituted C_1-C_4 alkyl, substituted C_1-C_4 alkyl, unsubstituted C_3-C_8 cycloalkyl, substituted C_3-C_8 cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C_1-C_4 alkyl, and substituted aryl C_1-C_4 alkyl;

the subscripts n and m are each independently 0 or 1, and at least one of n or m is 1, and the subscript q is 0 to 3;

L^1 is a first linker selected from the group consisting of unsubstituted C_2-C_6 alkylene, substituted C_2-C_6 alkylene, unsubstituted C_3-C_6 cycloalkylene, substituted C_3-C_6 cycloalkylene, unsubstituted arylene, substituted arylene, unsubstituted heteroarylene, and substituted heteroarylene; and

L^2 is a second linker selected from the group consisting of unsubstituted C_2-C_{12} alkylene, substituted C_2-C_{12} alkylene, unsubstituted arylene, substituted arylene, and combinations thereof.

120. **(Currently Amended)** The compound according to ~~**any one of Claims 118 and**~~ **claim** 119, wherein P^3 is –C(O)OR^2 or a carboxylic acid analog, wherein R^2 is selected from the group consisting of hydrogen, unsubstituted C_1-C_4 alkyl, substituted C_1-C_4 alkyl, unsubstituted C_3-C_8 cycloalkyl, and substituted C_3-C_8 cycloalkyl.

121. **(Currently Amended)** The compound according to ~~**any one of Claims 118 and**~~ **claim** 119, wherein P^3 is –C(O)OR^2 or a carboxylic acid analog, wherein R^2 is selected from the group consisting of hydrogen, methyl, and ethyl.

122. (Canceled)

123. (Withdrawn) The compound of Claim 119, wherein R^1 is phenyl.

124. (Withdrawn) The compound Claim 119, wherein R^1 is phenyl, wherein the phenyl is either unsubstituted or substituted with from one to three substituents selected from the group consisting of halogen, lower alkyl, lower halo alkyl, lower alkoxy, C_3-C_5 cycloalkyl, and cyano.

125. (Previously Presented) The compound of Claim 119, wherein P^1 is selected from the group consisting of –NHC(O)CH-, -OC(O)NH-, and –NHC(O)O-.

126. (Previously Presented) The compound of Claim 119, wherein P^1 is -NHC(O)CH-.

127. (Previously Presented) The compound of Claim 119, wherein L^1 is an alkylene of from 2 to 4 carbon atoms,

P^2 is not present; and

L^2 is an alkylene of from 2 to 8 carbon atoms.

128. (Previously Presented) The compound of Claim 119, wherein P^1 is selected from the group consisting of —NHC(O)NH—, -OC(O)NH— and —NHC(O)O—;

n is 0;

m is 1;

L^1 is selected from the group consisting of unsubstituted C_2-C_6 alkylene, unsubstituted C_3-C_6cycloalkylene, substituted C_3-C_6cycloalkylene, unsubstituted arylene, and substituted arylene;

L^2 is selected from the group consisting of unsubstituted C_2-C_6 alkylene and substituted C_2-C_6 alkylene; and

P^3 is selected from the group consisting of C_2-C_6 alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, —C(O)NHR^2, —C(O)NHS(O)$_2$R^2, —NHS(O)$_2$R^2, —C(O)OR^2, and carboxylic acid analogs, wherein R^2 is a member selected from the group consisting of hydrogen, unsubstituted C_1-C_4 alkyl, substituted C_1-C_4 alkyl, unsubstituted C_3-C_8 cycloalkyl, substituted C_3-C_8 cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C_1-C_4 alkyl, and substituted aryl C_1-C_4 alkyl.

129. (Currently Amended) A compound having the formula selected from the group consisting of:



;



,



,



,



,



,


Cl
O
N
H
N
H
O
O
CH3

,


Cl
O
N
H
N
H
O
O
O
CH3

,


Cl
O
N
H
N
H
O
H
N
O
CH3

,


Cl
O
N
H
N
H
H
N
O
CH3

,


Cl
O
N
H
N
H
H
N
O
O
CH3

,


Cl
O
H
N
N
H
N
H
N
O
CH3

,


O
N
H
N
H
OH
O

,


O
N
H
N
H
O
CH3
O

,


O
N
H
N
H
O
Et
O

,


O
N
H
N
H
H
N
Et
O

,


O
N
H
N
H
O
n-Pr
O

,


O
N
H
N
H
O
O

,



,



,



,



,



,



,



,


adamantyl,




Cl




(CH2)n1
CH3


CH3




O
N
H
N
H
O
O
O
CH3
O
N
H
N
H
O
O
O
O
N
H
N
H
O
O
O
O
CH3
O
N
H
N
H
O
O
O
H3C
CH3
O
N
H
N
H
O
O
O
CF3
O
N
H
N
H
O
O
O
imidazoyl
O
N
H
N
H
O
O
O
O
N
H
N
H
O
O
O













;



;



,



,



,



,



,



,



,



,



,



,



, **and**



,





~~wherein Z is O or NH;~~

~~R^3 is alkyl;~~

~~n1 is 1, 2, 3, 4, 6, 7, 9, 10, or 11;~~

~~n2 is 1, 2, 3, or 4;~~

~~n3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;~~

and their pharmaceutically acceptable salts.

130. (Canceled)

131. **(Currently Amended)** A compound having a formula



and their pharmaceutically acceptable salts, wherein

P^3 is selected from the group consisting of C_2-C_6 alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, -$NHS(O)_2R^2$, —$C(O)OR^2$ and carboxylic acid analogs, wherein R^2 is a member selected from the group consisting of hydrogen, unsubstituted C_1-C_4 alkyl, substituted C_1-C_4 alkyl, unsubstituted C_3-C_8 cycloalkyl, substituted C_3-C_8 cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C_1-C_4 alkyl, and substituted aryl C_1-C_4 alkyl;

~~the subscript m is 1;~~

L^1 is unsubstituted C_3-C_4 alkylene or substituted C_3-C_4 alkylene;

L^2 is unsubstituted C_8 alkylene or substituted C_8 alkylene.

132. (Previously Presented) A compound having the formula: